Moderna Therapeutics

Sustainability Report and Carbon Intensity Rankings

Is Moderna Therapeutics doing their part?

Their DitchCarbon score is 68

Moderna Therapeutics has a DitchCarbon Score of 68, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage and reduce its carbon intensity. A higher score would suggest even greater success in minimizing their environmental impact through lower carbon emissions.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Moderna Therapeutics is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Moderna Therapeutics operates in the United States, which has a low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.

The Ultimate Guide to Building Sustainability Into Procurement​​

In this guide you can learn about the three stages of sustainable procurement.

Stage 1) – Identify and Communicate
Sustainability Maturity

Stage 2) – Start to Give Preference to Mature Suppliers

Stage 3) – Make Climate Action a “Hard” Measure for Procurement

Over 500+ downloads

The Ultimate Guide to Building Sustainability Into Procurement​​

In this guide you can learn about the three stages of sustainable procurement.

Stage 1) – Identify and Communicate
Sustainability Maturity

Stage 2) – Start to Give Preference to Mature Suppliers

Stage 3) – Make Climate Action a “Hard” Measure for Procurement

16.64%

...this company is doing 16.64% better in emissions than the industry average.

Moderna Therapeutics, founded in 2010 and headquartered in Cambridge, operates within the research and development sector of the biotechnology industry. The company is a trailblazer in messenger RNA Therapeutics™, offering innovative in vivo drug technologies for a variety of diseases and conditions. Moderna collaborates with pharmaceutical giants like AstraZeneca, Alexion Pharmaceuticals, and Merck to develop and potentially commercialize its groundbreaking mRNA drugs.

emission intelligence's platform recommendations for Moderna Therapeutics

Moderna Therapeutics should undertake a thorough assessment of all direct emissions sources to identify opportunities for reduction.

Good news, Moderna Therapeutics has embraced SBTi commitments

Moderna Therapeutics has pledged to set science-based targets through the Science Based Targets initiative (SBTi) to reduce greenhouse gas emissions in line with climate science. This commitment means the company is working towards reducing its carbon footprint to prevent the worst impacts of climate change by aligning with the goals of the Paris Agreement.
Participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Looking for a specific company?

Search our company directory or contact us for custom data requests.